A non-coding RNA based classifier for favorable outcomes in clinically organ confined bladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract ...
Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.
Clinical outcomes in metastatic bladder cancer associated with mutations in Trithorax-group protein genes. Discordance in HER2 expression in primary and recurrent/metastatic lesions of upper tract ...
BERLIN -- A Chinese trial that screened advanced urothelial cancer patients for HER2-expression demonstrated a large survival benefit with a novel chemotherapy-free combination in the first-line ...
When contextualized with the developments across all genitourinary [GU] malignancies, especially renal cell carcinoma and ...
Aidixi combined with toripalimab significantly improved progression-free and overall survival in HER2-expressing urothelial carcinoma, regardless of cisplatin eligibility or HER2 expression status.
Noninvasive treatment options for NGB dysfunction include intermittent catheterization, Crede and Valsalva, indwelling catheterization, lifestyle changes/behavioral modification, and oral ...
There are different stages of bladder cancer depending on how the tumor has spread. The staging of bladder cancer can help a medical professional map out the best treatment plan and improve a person’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results